Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14618844 | 0.85 | HDAC1 (0.50) | HDAC1HDAC6NOTUMGAA | |
| SCHEMBL5579009 | 0.84 | HPGD (0.58) | NPC1RAB9AALDH1A1TSHRLMNA | |
| SCHEMBL5578970 | 0.83 | HDAC1 (0.49) | HDAC1HDAC6ALDH1A1TSHRUSP2 | |
| SCHEMBL5578576 | 0.80 | HDAC1 (0.47) | HDAC1HDAC6ALDH1A1LMNANOTUM | |
| SCHEMBL5578448 | 0.77 | NOTUM (0.48) | HDAC1HDAC6NOTUMKMT2A | |
| SCHEMBL5578839 | 0.76 | NOTUM (0.52) | HDAC1HDAC6NOTUM | |
| SCHEMBL5578784 | 0.75 | TSHR (0.42) | HDAC1HDAC6NPC1RAB9AALDH1A1 | |
| SCHEMBL5579351 | 0.75 | NOTUM (0.50) | HDAC1HDAC6NOTUM | |
| SCHEMBL5578527 | 0.74 | NOTUM (0.50) | HDAC1HDAC6NOTUM | |
| SCHEMBL5579089 | 0.73 | TSHR (0.46) | NPC1RAB9AALDH1A1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | claimed |
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | REN, AVPR2, RECQL | HDAC1 885/4885HDAC6 767/4885NPC1 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.